R
8.27
-0.56 (-6.34%)
| Previous Close | 8.83 |
| Open | 8.81 |
| Volume | 1,411,549 |
| Avg. Volume (3M) | 1,101,637 |
| Market Cap | 751,147,968 |
| Price / Book | 5.15 |
| 52 Weeks Range | |
| Earnings Date | 6 Nov 2025 |
| Diluted EPS (TTM) | -1.16 |
| Total Debt/Equity (MRQ) | 2.15% |
| Current Ratio (MRQ) | 8.43 |
| Operating Cash Flow (TTM) | -65.60 M |
| Levered Free Cash Flow (TTM) | -37.81 M |
| Return on Assets (TTM) | -52.85% |
| Return on Equity (TTM) | -95.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Rezolute, Inc. | Bullish | Bullish |
AIStockmoo Score
0.9
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 0.5 |
| Average | 0.88 |
|
Rezolute Inc is a biopharmaceutical company. The company develops novel, sustained-release injectable therapies. It applies proprietary formulation and manufacturing capabilities to known, well-characterized molecules to create differentiated, patent-protected therapies that have the potential to significantly improve existing standards of care. Its pipeline products include RZ358 and RZ402. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 9.65% |
| % Held by Institutions | 52.00% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 20.00 (Maxim Group, 141.84%) | Buy |
| Median | 16.00 (93.47%) | |
| Low | 14.00 (HC Wainwright & Co., 69.29%) | Buy |
| Average | 16.50 (99.52%) | |
| Total | 4 Buy | |
| Avg. Price @ Call | 7.82 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Guggenheim | 22 Sep 2025 | 15.00 (81.38%) | Buy | 8.14 |
| Maxim Group | 19 Sep 2025 | 20.00 (141.84%) | Buy | 7.70 |
| BTIG | 18 Sep 2025 | 17.00 (105.56%) | Buy | 8.20 |
| HC Wainwright & Co. | 03 Sep 2025 | 14.00 (69.29%) | Buy | 7.24 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 15 Oct 2025 | Announcement | Rezolute to Participate in Upcoming Investor Conferences |
| 09 Oct 2025 | Announcement | Rezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) |
| 17 Sep 2025 | Announcement | Rezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business Update |
| 02 Sep 2025 | Announcement | Rezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor Hyperinsulinism |
| 27 Aug 2025 | Announcement | Rezolute to Participate in Upcoming Investor Conferences |
| 20 Aug 2025 | Announcement | Rezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial Officer |
| 22 Jul 2025 | Announcement | Rezolute to Participate in the BTIG Virtual Biotechnology Conference |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |